title: Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine.
abstract: Alpha-2-(Difluoromethyl)-dl-ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, has been shown to suppress skin carcinogenesis in murine models after oral or topical administration. We designed a randomized, placebo-controlled study using a topical hydrophilic ointment formulation with or without 10% (w/w) DFMO. Forty-eight participants with moderate-severe actinic keratoses (AKs) on their forearms (i.e., at least 10 well-circumscribed lesions on the lateral surface) completed a 1-month run-in on placebo ointment. Before randomization, all lateral forearm AKs were circled, counted, photographed, and skin biopsies were obtained for DFMO and polyamine levels. Then participants were randomized to receive DFMO ointment on the right versus the left forearm and placebo hydrophilic ointment on the contralateral forearm twice daily for 6 months. DFMO was not detected in the blood of any subject, and there were no systemic toxicities. None of a subsample of 17 placebo forearms had measurable concentrations of DFMO, whereas 13 of the corresponding DFMO-treated forearms had high DFMO skin levels. As compared with placebo, the 6-month DFMO treatment caused a 23.5% reduction in the number of AKs (P = 0.001) as well as significant suppression of AK biopsy spermidine levels (26%; P = 0.04). Seven of the 48 (14.6%) participants experienced severe (2; 4.2%) or moderate (5; 10.4%) inflammatory reactions on their DFMO-treated arms which required dosing modification. Topical DFMO for 6 months can reduce the number of AK lesions and skin spermidine concentrations in high-risk participants and deserves additional study as a skin cancer chemopreventive agent.
authors.affiliation: Arizona Cancer Center, University of Arizona, Tucson 85724, USA. dalberts@azcc.arizona.edu
authors.forename: D S
authors.initials: DS
authors.lastname: Alberts
authors.forename: R T
authors.initials: RT
authors.lastname: Dorr
authors.forename: J G
authors.initials: JG
authors.lastname: Einspahr
authors.forename: M
authors.initials: M
authors.lastname: Aickin
authors.forename: K
authors.initials: K
authors.lastname: Saboda
authors.forename: M J
authors.initials: MJ
authors.lastname: Xu
authors.forename: Y M
authors.initials: YM
authors.lastname: Peng
authors.forename: R
authors.initials: R
authors.lastname: Goldman
authors.forename: J A
authors.initials: JA
authors.lastname: Foote
authors.forename: J A
authors.initials: JA
authors.lastname: Warneke
authors.forename: S
authors.initials: S
authors.lastname: Salasche
authors.forename: D J
authors.initials: DJ
authors.lastname: Roe
authors.forename: G T
authors.initials: GT
authors.lastname: Bowden
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000518:Eflornithine / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007642:Keratosis / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D009824:Ointments; D010787:Photosensitivity Disorders / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009824:Ointments; D000518:Eflornithine